JAMA Oncology (@JAMAOnc) / X

JAMA Oncology

18.8K posts

JAMA Oncology

@JAMAOnc

JAMA Oncology is a member of the JAMA Network, a consortium of peer-reviewed, general medical and specialty publications.

Chicago, IL

ja.ma/tjamaoncology

Joined September 2014

JAMA Oncology
@JAMAOnc
Nov 2, 2023
This study found that women with breast cancer who used vaginal estrogen therapy (vaginal creams or vaginal tablets), compared with no hormone replacement therapy use, did not appear to have an increased risk of early breast cancer-specific mortality. ja.ma/3QpcVL2
JAMA Oncology
@JAMAOnc
Apr 7, 2024
Most cancer drugs granted accelerated approval did not demonstrate benefit in overall survival or quality of life within 5 years of accelerated approval. ja.ma/3J3zZMi #AACR24
JAMA Oncology
@JAMAOnc
Aug 10, 2025
Viewpoint: The rise in early-onset cancers in individuals under 50 may be explained by accelerated biological aging, with aging and cancer sharing common mechanisms. ja.ma/4myVLcs
JAMA Oncology
@JAMAOnc
Feb 15, 2023
This study found that autologous tumor lystate-loaded dendritic cell vaccination plus standard of care (SOC) was associated with improved survival in both newly diagnosed & recurrent glioblastoma compared with matched controls who received SOC treatment. ja.ma/3knl0Ud
JAMA Oncology
@JAMAOnc
Nov 18, 2022
This study found that autologous tumor lystate-loaded dendritic cell vaccination plus standard of care (SOC) was associated with improved survival in both newly diagnosed & recurrent glioblastoma compared with matched controls who received SOC treatment. ja.ma/3Ekm2Xm
JAMA Oncology
@JAMAOnc
Jul 19, 2018
Patients who pursued #ComplementaryMedicine for breast, prostate, colon or lung cancer had a significantly worse overall survival, likely explained by delays in or refusal to pursue conventional #cancer therapies ja.ma/2LbVSh2 @sky__john @cpgYALE @YaleCOPPER @jamesbyu
JAMA Oncology
@JAMAOnc
May 25, 2025
Viewpoint discusses how "skimming the median" can exaggerate survival gains in clinical trials, underscoring the need to critically evaluate Kaplan-Meier curves alongside hazard ratios. ja.ma/4jePW1F
JAMA Oncology
@JAMAOnc
Dec 26, 2017
You send plasma from same patient for cell-free DNA testing to two different companies. In nearly all cases, you get different results from each. Data offer humbling reminder of imprecision of #PrecisionMedicine. ja.ma/2BfT8G4
JAMA Oncology
@JAMAOnc
Jun 2, 2025
Phase 3 oncology RCTs often report positive results based on alternative end points, but actual improvements in overall survival or quality of life are rare, highlighting need to prioritize these outcomes in future research & regulatory processes. #ASCO25 ja.ma/3FCoVHI
JAMA Oncology
@JAMAOnc
Mar 2, 2025
Viewpoint: The growing use of immune checkpoint inhibitors in cancer treatment brings significant therapeutic benefits but also long-term immune-related adverse effects. ja.ma/4gYT8NR
JAMA Oncology
@JAMAOnc
Jun 1, 2025
Viewpoint: The rise in early-onset cancers in individuals under 50 may be explained by accelerated biological aging, with aging and cancer sharing common mechanisms. ja.ma/3Hdx1Hb
JAMA Oncology
@JAMAOnc
May 20, 2024
After accounting for biases and confounders, cancer clinical trial participation was not associated with longer survival. ja.ma/44NAqEq
JAMA Oncology
@JAMAOnc
May 3, 2025
Most viewed this week from @JAMAOnc: Prophylactic IV magnesium administration was associated with a lower risk of cisplatin-associated acute kidney injury (CP-AKI) in patients with cancer undergoing cisplatin chemotherapy. ja.ma/44fFHqa
JAMA Oncology
@JAMAOnc
Jun 21, 2025
Viewpoint: Prostate cancer screening is shifting toward a more beneficial and less harmful approach by using MRI-targeted strategies, which reduce unnecessary biopsies and overdiagnosis. ja.ma/45rVOSb @IvoSchootsNL